本帖最后由 老马 于 2013-3-13 13:43 编辑 3 |' b U, f- X$ u
2 e: V0 }/ h/ R/ y/ |8 K" S
健择(吉西他滨)+顺铂+阿瓦斯汀0 @: o! f' q5 X1 N& p
Gemzar +Cisplatin + Avastin
1 U( s5 U% }% Ihttp://annonc.oxfordjournals.org/content/21/9/1804.full
" H n. I) `3 J2 iOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) G8 a* ^* `& S& M9 k" c, c+ c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 `+ \+ W( t- I0 ?Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 8 `: z. v- E: p$ O, s6 j7 t
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1040)
$ O. h7 y1 ~ R" n4 J, Y1 d5 r, {
华为网盘附件: \2 s+ q7 i& A2 Z% a; L8 {
【华为网盘】ava.JPG$ h1 Z/ }% F: r3 {; R
|